Molecular Characterization of Induced Neuronal Cells in Parkinson's Disease

Molecular Characterization of Induced Neuronal Cells Derived From Fibroblasts of Patients With Parkinson's Disease

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05797779

Enrollment

Registered

2023-04-04

Start date

2021-03-25

Completion date

2025-03-25

Last updated

2023-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

To describe the molecular, electrophysiological and morphological expression profile of dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.

Interventions

PROCEDURESkin biopsy

Punch biopsy of the skin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Subjects aged 18 years or older 2. Patients with Parkinson's disease, according to the most recent diagnostic criteria 3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study

Exclusion criteria

1. Patients affected by drug-induced parkinsonism or atypical parkinsonian disorders 2. Patients with neurological diseases other than Parkinson's disease 3. Inability to sign an informed consent 4. Severe psychiatric diseases

Design outcomes

Primary

Measure	Time frame	Description
Neurophysiological characterization of dopaminergic neurons derived from patients with Parkinson's disease.	Baseline	To evaluate the firing frequency in the dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.
Biochemical characterization of dopaminergic neurons derived from patients with Parkinson's disease.	Baseline	To determine the amount of dopamine released from differentiated neurons derived from fibroblasts of patients with Parkinson's disease.
α-synuclein misfolding in dopaminergic neurons derived from patients with Parkinson's disease.	Baseline	To document the presence of abnormal accumulation of misfolded alpha-synuclein in the dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.

Countries

Italy

Contacts

Primary ContactGuido Alessandro Primiano, MD

guidoalessandro.primiano@policlinicogemelli.it+390630156433

Backup ContactFlavia Torlizzi

flavia.torlizzi@policlinicogemelli.it0630156433

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026